The DOI matches its Crossref record.
Safety and Efficacy of Degradable Starch Microspheres Transcatheter Arterial Chemoembolization as a Bridging Therapy in Patients with Early Stage Hepatocellular Carcinoma and Child-Pugh Stage B Eligible for Liver Transplant
Abstract
In patients with early-stage hepatocellular carcinoma, awaiting liver transplantation, current guidelines by AASLD and ESMO recommend a bridging therapy with a loco-regional treatment to prevent progression outside transplantation criteria. The standard of care in delaying disease progression has been recognized to be the transarterial chemoembolization. Permanent occlusion of tumor feeding vessels has effects on tumour stromal microenvironment by inducing intra- and intercellular signaling processes counteracting hypoxia, such as the release of vascular endothelial growth factor, a promoter of neoangiogenesis, tumour proliferation and metastatic growth. Among chemoembolization interventions, TACE with degradable starch microspheres represents an alternative to conventional cTACE and DEB-TACE and it minimizes detrimental effects on tumour stromal microenvironment, guaranteeing a transient occlusion of tumour feeding arteries and avoiding VEGF overexpression.Between January 2015 and September 2020, 54 consecutive patients with early-stage hepatocellular carcinoma and Child-Pugh stage B, who had undergone DSM-TACE as a bridging therapy while awaiting liver transplantation, were eligible for the study. A total of 154 DSM-TACE was performed, with a mean number of 2.85 procedures per patient. 18 patients (33.3%) succeeded in achieving liver transplantation, with a mean waiting time-to-transplantation of 11.7 months. The cumulative rates of patients still active on the WL at 6 months were about 91 and 93% when considering overall drop-out and tumour-specific drop-out respectively. Overall survival was about 96% at 6 months and 92% at 12 months. 17 patients experienced adverse events after the chemoembolizations. For patients with HCC in the transplant waiting list and within the Child-Pugh B stage, life expectancy may be dominated by the liver dysfunction, rather than by the tumour progression itself. In this population subset, the choice of LRT is critical because LRT itself could become a dangerous tool that is likely to precipitate liver dysfunction to an extent that survival is shortened rather than prolonged. Hence, the current study demonstrates that DSM-TACE is not far from being an ideal LRT, because it has an excellent safety profile, maintaining an efficacy that guarantees a clear advantage on the dropout rate with respect to the non-operative strategy, thus justifying its use.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Arterial introducer sheaths ranging in size from 4 to 8 Fr are used in most interventional radiology procedures [1,2,3,4,5,6,7,8,9,10,11,12].”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
No references could be resolved yet.
Research works printed but not linked: 56
- Alba, 2008, Transcatheter arterial chemoembolization in patients with hepatocellular carcinoma on the waiting list for orthotopic liver transplantation, Am. J. Roentgenol., 190, 1341, 10.2214/ajr.07.2972 · doi:10.2214/ajr.07.2972
- Ayaru, 2007, Unmasking of α-fetoprotein-specific CD4+ T cell responses in hepatocellular carcinoma patients undergoing embolizationfic CD4( + ) T cell responses in hepatocellular carcinoma patients undergoing embolization, J. Immunol., 178, 1914, 10.4049/jimmunol.178.3.1914 · DOI · Paper page
- Basile, 2012, Quality-improvement guidelines for hepatic transarterial chemoembolization, Cardiovasc. Intervent Radiol., 35, 765, 10.1007/s00270-012-0423-z · DOI
- Bolondi, 2012, Heterogeneity of patients with intermediate (BCLC B) Hepatocellular Carcinoma: proposal for a subclassification to facilitate treatment decisionsfication to facilitate treatment decisions, Semin. Liver Dis., 32, 348, 10.1055/s-0032-1329906 · DOI · Paper page
- Brown, 2016, Randomized trial of hepatic artery embolization for hepatocellular carcinoma using doxorubicin-eluting microspheres compared with embolization with microspheres alone, J. Clin. Oncol., 34, 2046, 10.1200/jco.2015.64.0821 · DOI · Paper page
- Carmeliet, 2005, Angiogenesis in life, disease and medicine, Nature, 438, 932, 10.1038/nature04478 · DOI · Paper page
- Cescon, 2013, Hepatocellular carcinoma locoregional therapies for patients in the waiting list. Impact on transplantability and recurrence rate, J. Hepatol., 58, 609, 10.1016/j.jhep.2012.09.021 · DOI · Paper page
- Dan, 2013, Postoperative neutrophil-to-lymphocyte ratio change predicts survival of patients with small hepatocellular carcinoma undergoing radiofrequency ablation, PLoS One, 8, e58184, 10.1371/journal.pone.0058184 · DOI
- DuBay, 2011, Radiofrequency ablation of hepatocellular carcinoma as a bridge to liver transplantation, Hpb, 13, 24, 10.1111/j.1477-2574.2010.00228.x · doi:10.1111/j.1477-2574.2010.00228.x
- Filippiadis, 2017, Cirse quality assurance document and standards for classification of complications: the cirse classification systemfication of complications: the cirse classification system, Cardiovasc. Intervent. Radiol., 40, 1141, 10.1007/s00270-017-1703-4 · DOI · Paper page
- Fontana, 2002, Percutaneous radiofrequency thermal ablation of hepatocellular carcinoma: a safe and effective bridge to liver transplantation, Liver Transplant., 8, 1165, 10.1053/jlts.2002.36394 · DOI
- Forner, 2010, Current strategy for staging and treatment: the BCLC update and future prospects, Semin. Liver Dis., 30, 061, 10.1055/s-0030-1247133 · DOI · Paper page
- Galle, 2018, EASL clinical practice guidelines: management of hepatocellular carcinoma, J. Hepatol., 69, 182, 10.1016/j.jhep.2018.03.019 · DOI · Paper page
- Gross, 2020, Transarterial chemoembolisation (TACE) with degradable starch microspheres (DSM) and anthracycline in patients with locally extensive hepatocellular carcinoma (HCC): safety and efficacyficacy, Cardiovasc. Intervent. Radiol., 43, 402, 10.1007/s00270-019-02364-w · doi:10.1007/s00270-019-02364-w
- Gruber-Rouh, 2018, Transarterial chemoembolization (TACE) using mitomycin and lipiodol with or without degradable starch microspheres for hepatocellular carcinoma: comparative study, BMC Cancer, 18, 188, 10.1186/s12885-018-4099-x · doi:10.1186/s12885-018-4099-x
- Harnois, 1999, Preoperative hepatic artery chemoembolization followed by orthotopic liver transplantation for hepatocellular carcinoma, Liver Transpl., 5, 192, 10.1002/lt.500050307 · doi:10.1002/lt.500050307
- Hayashi, 2004, Hepatic artery chemoembolization for hepatocellular carcinoma in patients listed for liver transplantation, Am. J. Transpl., 4, 782, 10.1111/j.1600-6143.2004.00413.x · doi:10.1111/j.1600-6143.2004.00413.x
- Heimbach, 2018, AASLD guidelines for the treatment of hepatocellular carcinoma, Hepatology, 67, 358, 10.1002/hep.29086 · DOI · Paper page
- Iezzi, 2016, Transarterial chemoembolization with degradable starch microspheres (DSM-TACE): an alternative option for advanced HCC patients? Preliminary results, Eur. Rev. Med. Pharmacol. Sci., 20, 2872
- Kang, 2020, Conventional versus small doxorubicin-eluting bead transcatheter arterial chemoembolization for treating Barcelona clinic liver cancer stage 0/A hepatocellular carcinoma, Cardiovasc. Intervent. Radiol., 43, 55, 10.1007/s00270-019-02349-9 · doi:10.1007/s00270-019-02349-9
- Kirchhoff, 2006, Chemoocclusion vs chemoperfusion for treatment of advanced hepatocellular carcinoma: a randomised trial, Eur. J. Surg. Oncol. (Ejso), 32, 201, 10.1016/j.ejso.2005.11.003 · doi:10.1016/j.ejso.2005.11.003
- Kulik, 2018, Therapies for patients with hepatocellular carcinoma awaiting liver transplantation: a systematic review and meta-analysis, Hepatology, 67, 381, 10.1002/hep.29485 · DOI · Paper page
- Lammer, 2010, Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study, Cardiovasc. Intervent. Radiol., 33, 41, 10.1007/s00270-009-9711-7 · DOI · Paper page
- Lee, 2017, Radiofrequency ablation of hepatocellular carcinoma as bridge therapy to liver transplantation: a 10-year intention-to-treat analysis, Hepatology, 65, 1979, 10.1002/hep.29098 · DOI
- Lencioni, 2013, Chemoembolization of hepatocellular carcinoma, Semin. Intervent. Radiol., 30, 3, 10.1055/s-0033-1333648 · DOI · Paper page
- Lencioni, 2016, Lipiodol transarterial chemoembolization for hepatocellular carcinoma: a systematic review of efficacy and safety dataficacy and safety data, Hepatology, 64, 106, 10.1002/hep.28453 · DOI · Paper page
- Lencioni, 2010, Modified RECIST (mRECIST) assessment for hepatocellular carcinoma, Semin. Liver Dis., 30, 052, 10.1055/s-0030-1247132 · DOI · Paper page
- Llovet, Prognosis of hepatocellular carcinoma: the BCLC staging classification, Semin. Liver Dis., 19, 329, 10.1055/s-2007-1007122 · DOI · Paper page
- Llovet, Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation, Hepatology, 30, 1424, 10.1002/hep.510300629 · DOI · Paper page
- Llovet, 2002, Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial, The Lancet, 359, 1734, 10.1016/s0140-6736(02)08649-x · DOI · Paper page
- Lo, 2002, Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma, Hepatology, 35, 1164, 10.1053/jhep.2002.33156 · DOI · Paper page
- Majno, 2011, Is the treatment of hepatocellular carcinoma on the waiting list necessary?, Liver Transpl., 17, S98, 10.1002/lt.22391 · doi:10.1002/lt.22391
- Mauri, 2016, TAE for HCC: when the old way is better than the new ones!!!, Cardiovasc. Intervent. Radiol., 39, 799, 10.1007/s00270-016-1340-3 · doi:10.1007/s00270-016-1340-3
- 2016, Squaring the circle of selection and allocation in liver transplantation for HCC: An adaptive approach, Hepatology, 63, 1707, 10.1002/hep.28420 · DOI
- Mazzaferro, 1996, Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis, N. Engl. J. Med., 334, 693, 10.1056/nejm199603143341104 · DOI · Paper page
- Millonig, 2007, Response to preoperative chemoembolization correlates with outcome after liver transplantation in patients with hepatocellular carcinoma, Liver Transpl., 13, 272, 10.1002/lt.21033 · DOI
- Mizukoshi, 2011, Comparative analysis of various tumor-associated antigen-specific t-cell responses in patients with hepatocellular carcinomafic t-cell responses in patients with hepatocellular carcinoma, Hepatology, 53, 1206, 10.1002/hep.24149 · DOI · Paper page
- Niessen, 2014, Degradable starch microspheres versus ethiodol and doxorubicin in transarterial chemoembolization of hepatocellular carcinoma, J. Vasc. Interv. Radiol., 25, 240, 10.1016/j.jvir.2013.10.007 · doi:10.1016/j.jvir.2013.10.007
- Oken, 1982, Toxicity and response criteria of the eastern cooperative Oncology group, Am. J. Clin. Oncol., 5, 649, 10.1097/00000421-198212000-00014 · DOI · Paper page
- Oligane, 2017, Effect of bridging local-regional therapy on recurrence of hepatocellular carcinoma and survival after orthotopic liver transplantation, Radiology, 282, 869, 10.1148/radiol.2016160288 · doi:10.1148/radiol.2016160288
- Orlacchio, 2018, Repeated transarterial chemoembolization with degradable starch microspheres (DSMs-TACE) of unresectable hepatocellular carcinoma: a prospective pilot study, Cmir, 14, 637, 10.2174/1573405613666170616123657 · doi:10.2174/1573405613666170616123657
- Orlacchio, 2020, Degradable starch microspheres transarterial chemoembolization (DSMs-TACE) in patients with unresectable hepatocellular carcinoma (HCC): long-term results from a single-center 137-patient cohort prospective study, Radiol. Med., 125, 98, 10.1007/s11547-019-01093-x · doi:10.1007/s11547-019-01093-x
- Pieper, 2015, Temporary arterial embolization of liver parenchyma with degradable starch microspheres (EmboCeptS) in a swine model, Cardiovasc. Intervent. Radiol., 38, 435, 10.1007/s00270-014-0966-2 · doi:10.1007/s00270-014-0966-2
- Pompili, 2013, Bridging and downstaging treatments for hepatocellular carcinoma in patients on the waiting list for liver transplantation, Wjg, 19, 7515, 10.3748/wjg.v19.i43.7515 · DOI
- Ravaioli, 2008, Liver transplantation for hepatocellular carcinoma: results of down-staging in patients initially outside the Milan selection criteria, Am. J. Transpl., 8, 2547, 10.1111/j.1600-6143.2008.02409.x · DOI · Paper page
- Sandow, 2018, Assessment of response to transcatheter arterial chemoembolization with doxorubicin-eluting microspheres: tumor biology and hepatocellular carcinoma recurrence in a 5-year transplant cohort, Radiology, 286, 1072, 10.1148/radiol.2017170731 · doi:10.1148/radiol.2017170731
- Schicho, 2016, Impact of different embolic agents for transarterial chemoembolization (TACE) procedures on systemic vascular endothelial growth factor (VEGF) levels, J. Clin. Transl. Hepatol., 4, 288, 10.14218/JCTH.2016.00058 · DOI
- Schicho, 2017, Transarterial chemoembolization (TACE) with degradable starch microspheres (DSM) in hepatocellular carcinoma (HCC): multi-center results on safety and efficacyficacy, Oncotarget, 8, 72613, 10.18632/oncotarget.19997 · doi:10.18632/oncotarget.19997
- Tan, 2018, Bridging therapies to liver transplantation for hepatocellular carcinoma: a bridge to nowhere?, Ann. Hepatobiliary Pancreat. Surg., 22, 27, 10.14701/ahbps.2018.22.1.27 · doi:10.14701/ahbps.2018.22.1.27
- Vogel, 2018, Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Ann. Oncol., 29, iv238, 10.1093/annonc/mdy308 · DOI · Paper page
- Wiesner, 2004, Liver transplantation for hepatocellular cancer: the impact of the MELD allocation policy, Gastroenterology, 127, S261, 10.1053/j.gastro.2004.09.040 · DOI · Paper page
- Yao, 2002, Liver transplantation for hepatocellular carcinoma: analysis of survival according to the intention-to-treat principle and dropout from the waiting list, Liver Transpl., 8, 873, 10.1053/jlts.2002.34923 · DOI · Paper page
- Yao, 2005, A prospective study on downstaging of hepatocellular carcinoma prior to liver transplantation, Liver Transpl., 11, 1505, 10.1002/lt.20526 · DOI · Paper page
- Yao, 2015, Downstaging of hepatocellular cancer before liver transplant: long-term outcome compared to tumors within Milan criteria, Hepatology, 61, 1968, 10.1002/hep.27752 · DOI · Paper page
- Zerbini, 2010, Radiofrequency thermal ablation for hepatocellular carcinoma stimulates autologous NK-cell response, Gastroenterology, 138, 1931, 10.1053/j.gastro.2009.12.051 · DOI · Paper page
- Zhang, 2018, Association of sustained response duration with survival after conventional transarterial chemoembolization in patients with hepatocellular carcinoma, JAMA Netw. Open, 1, e183213, 10.1001/jamanetworkopen.2018.3213 · DOI
Cited by
Minici, R., Serra, R., Maglia, C., Guzzardi, G., Spinetta, M., Fontana, F., Venturini, M., & Laganà, D. (2023) · Journal of Personalized Medicine · doi:10.3390/jpm13050812 · Cited by 20
Self-citation
Metadata
- Authors
- Minici, R., Ammendola, M., Manti, F., Siciliano, M. A., Giglio, E., Minici, M., Melina, M., Currò, G., & Laganà, D.
- Venue
- Frontiers in Pharmacology
- Publisher
- Frontiers Media SA
- Published
- 2021-04-09
- Volume
- 12
- ISSN
- 1663-9812
- Cited by
- 17
- References
- 0
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Safety and Efficacy of Degradable Starch Microspheres Transcatheter Arterial Chemoembolization as a Bridging Therapy in Patients with Early Stage Hepatocellular Carcinoma and Child-Pugh Stage B Eligible for Liver Transplant. https://app.cochat.ai/papers/10.3389/fphar.2021.634084
- The paper
- Minici, R., Ammendola, M., Manti, F., Siciliano, M. A., Giglio, E., Minici, M., Melina, M., Currò, G., & Laganà, D. (2021). Safety and Efficacy of Degradable Starch Microspheres Transcatheter Arterial Chemoembolization as a Bridging Therapy in Patients with Early Stage Hepatocellular Carcinoma and Child-Pugh Stage B Eligible for Liver Transplant. Frontiers in Pharmacology. https://doi.org/10.3389/fphar.2021.634084
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.